Bastiaan van der Baan - Sep 26, 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
President and CEO, Director
Signature
/s/ Bastiaan van der Baan
Stock symbol
LIXT
Transactions as of
Sep 26, 2023
Transactions value $
$0
Form type
4
Date filed
9/27/2023, 06:05 AM
Previous filing
Jul 7, 2023
Next filing
Oct 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +250K $0.00 250K Sep 26, 2023 Common 250K $1.95 Direct F1
transaction LIXT Options to Purchase Common Stock Award $0 +10K $0.00 10K Jun 30, 2023 Common 10K $5.88 Direct
transaction LIXT Options to Purchase Common Stock Award $0 +25K $0.00 25K Jun 17, 2022 Common 25K $7.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested.

Remarks:

NOTE: Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of common stock set forth above for all transactions entered into prior to that date have been adjusted to reflect the reverse stock split.